

#### UiO **Institutt for medisinske basalfag** Det medisinske fakultet

MF9130E – Introductory course in statistics, spring 2024

Lecture: Study designs: epidemiological designs and concepts, principles of clinical trials

Jo S Stenehjem (slides also by Marit B Veierød), Senior Researcher, Dept of Biostatistics, University of Oslo Senior Researcher, Dept of Research, Cancer Registry of Norway





# Outline

- 08.30-10.00: Part I. Epidemiological studies
  - 09.40-10:00: Mini-groups, discussion
- 10.00-10.15: Break
- 10:15-11.30: Part II. Clinical studies/summary
  - 10:10-11:30: Mini-groups, discussion
- 11:30-11:45: Part III. Questions



# **Readings/literature**

- Kapittel 9&10. Aalen (red), Frigessi, Moger, Scheel, Skovlund, Veierød. Statistiske metoder i medisin og helsefag. Gyldendal Akademisk 2006
- Chapter 34. Kirkwood, Sterne. *Medical Statistics*. 2nd ed. Blackwell Science Ltd 2003'

Additional readings:

- Chapter 1. Veierød, Lydersen, Laake (eds.) *Medical statistics in clinical and epidemiological research*. Gyldendal Akademisk, 2012. www.medicalstatistics.no
- Laake, Hjartåker, Thelle, Veierød (red). Epidemiologiske og kliniske forskningsmetoder. Gyldendal akademisk, 2007.











## Learning outcomes

The participants shall get a basic understanding in the following areas: Elementary probability; probability distributions: binomial distribution and normal distribution; design of clinical trials and epidemiological studies; statistical theory of estimation; construction of confidence intervals; testing statistical hypotheses; analysis of paired data and comparison of two samples; analysis of tables; linear regression analysis with one or several explanatory variables; survival analysis.

UiO **Institutt for medisinske basalfag** Det medisinske fakultet

## Learning outcomes for the lecture

- Know the key-features of different designs
- When we can use different designs
- Pros and cons with different designs
- Briefly methods used for the different designs more later this week

Det medisinske fakultet

#### Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

# **Outline Part I. Epidemiological studies:**

- Overview
- Ecological
- Cross-sectional
- Case-control
- Cohort
- Summary methods
- Case: Group discussion

Det medisinske fakultet

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

# **Epidemiology definition (Porta, 2014):**

The study of the occurrence and distribution of health-related events, states and processes in specified populations, including the study of the determinants influencing such processes, and the application of this knowledge to control relevant health problems. Det medisinske fakultet

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

# Epidemiologi definisjon (Porta, 2014):

The study of the occurrence and distribution of health-related events, states and processes in specified populations, including the study of the determinants influencing such processes, and the application of this knowledge to control relevant health problems.

- Occurrence and distribution (norsk: forekomst)
- Health-related events, states and processes (norsk: utfall/sykdom)
- Populations (norsk: befolkninger)
- Determinants (norsk: årsaker)

Det medisinske fakultet

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions Simple definition

The study of distribution and causes of disease in a population

Det medisinske fakultet

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

# **Distribution and causes of disease**

At the core of epidemiology lies the ability to acquire knowledge about the causes and distribution of a disease

We have to ask ourselves:

- Who get sick? (distribution)
- Why does some get sick, while others does not? (causes)

Det medisinske fakultet

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

# Distribution

The distribution may be studied by some central axes:

- **Time:** How does the disease distirubtion develop over time? Does it change?
- **Age:** Is the incidence different in different age group?
- **Place:** Is the incidence different at different places?

Det medisinske fakultet

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

# **Causes** / exposures – some examples

#### **External factors**

Host factors

Does the incidence differ among the exposed vs the unexposed?

- Occupation
- Environment
- Biological (virus, bactera, toxines)
- Diagnostic pressure?

- Chronic diseases
- Immunological

Det medisinske fakultet

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

# Tripod - analogy

Analogy to taking photos:

Epidemiological studies are like photo cameras on tripods; they need three legs to not give a biased picture of reality

Epidemiological studies precision and validity depend on:

- Good exposure data
- Good endpoint data
- Good control on the population



Det medisinske fakultet

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

## **Observational designs**

- Ecological studies
- Cross-sectional studies
- Case-control studies
- Cohort studies

Det medisinske fakultet

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

# **Ecological studies**

Comparison of the frequency of disease in different populations with an average distribution of the exposure within these populations – group level comparisons



**Figure 16–1.** Relationship of national per capita (From Carroll, 1975; reproduced with permisfat intake with risk of breast cancer mortality. sion.)

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

# **Ecological studies cont.**

- Armstrong and Doll (1975) studied the association between per capita meat consumption and incidence of colon cancer, based on data from 23 countries. A very strong correlation between meat consumption and colon cancer was observed. Pearson's correlation coefficient was 0.89 for women and 0.85 for men.
- Exposure and outcome are measured at the group level

Det medisinske fakultet

# **Ecological studies cont.**

Stat. sig. correlation between number of familial hypercholesterolemia diagnoses and statin users.

However, we cannot claim any causal relation in this study, and studies of data at an individual level are warranted to adequately address the association between statin use and genetically verified FH.



**Fig. 3.** Number of genetically diagnosed children aged 10-19 years with familial hypercholesterolemia and number of statin/statins + ezetimibe users in corresponding age group in Norway between 2008 and 2018. The Kendall's tau correlation = 0.96, p < 0.001.

Det medisinske fakultet

#### Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

### **Ecological studies cont.**

#### The NEW ENGLAND JOURNAL of MEDICINE

#### Chocolate Consumption, Cognitive Function, and Nobel Laureates

Franz H. Messerli, M.D.

#### DISCUSSION

The principal finding of this study is a surprisingly powerful correlation between chocolate intake per capita and the number of Nobel laureates in various countries. Of course, a correlation between X and Y does not prove causation but indicates that either X influences Y, Y influences X, or X and Y are influenced by a common underlying mechanism. However, since chocolate consumption has been documented to improve cognitive function, it seems most likely that in a dose-dependent way, chocolate intake provides the abundant fertile ground needed for the sprouting of Nobel laureates. Obviously, these findings are hypothesis-generating only and will have to be tested in a prospective, randomized trial.



Det medisinske fakultet

#### Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

# **Ecological studies cont.**

Disadvantages:

- Not data at an individual level
- Does not indicate whether or not it is individuals with high exposure that get sick.
- Proper control for confounding by other factors is not possible.
- Ecological studies alone are insufficient to form a basis for public health guidelines.

Advantages:

- Heterogeneity in the exposure
- May be used to describe group phenomena e.g. political elections

Det medisinske fakultet

#### Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

# **Ecological studies cont.**

Methods used

- Correlations
- Comparison of group-level prevalence or incidence rates
- Regression techniques to examine trends in rates; i.e. to check if rates have changed significantly over time.

Det medisinske fakultet

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

## **Observational designs**

- Ecological studies
- Cross-sectional studies
- Case-control studies
- Cohort studies

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

## **Cross-sectional studies**

- Useful to determine the prevalence of a specific characteristic, disease, or exposure, at a given specified time.
- Form the basis for administrative and political decisions.

UiO **Institutt for medisinske basalfag** Det medisinske fakultet

## **Cross-sectional studies**

- **Prevalence** measures *burden* of disease
- Insidens measures *risk* of disease



#### Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

# Cross-sectional studies cont.

#### Example 1 (Lien et al., UNGHUBRO)

- A cross-sectional population-based survey was conducted with10th-grade students in Oslo, Norway (n = 5498).
  Hopkins Symptom Checklist and Strengths and Difficulties Questionnaire to assess mental health outcomes.
- **Conclusion:** High consumption levels of sugar-containing soft drinks were associated with mental health problems even after adjustment for possible confounders.
- **Question:** Soft drinks causes psychological distress or distressed adolescents choose to drink sugar-containing soft drinks?

#### Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

# **Cross-sectional studies cont.**

#### Example 2: from the HUNT-study

- Consist of several cross-sectional surveys conducted in the Nord-Trøndelag county
- **Aim:** To examine the association between adiposity, physical activity and hypertension
- **Question:** By using data measured at the same time from HUNT 1, can we say anything about causality?
  - Physical inactivity may lead to hypertension
  - Hypertension may lead to inactivity
- **Important:** Cross-sectional studies may be transformed to a longitudinal study.
- Longitudinal study=linkage of two or more cross-sectional studies and thereby establish a temporal component.





# Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions Cross-sectional studies cont.

#### **Example 3: from the HUNT-study**

- **Aim:** To examine the association between physical activity and colorectal cancer risk
- Methods: Linkage between HUNT1 and CRN. Prospective follow-up 1984-2002
- **Important:** Cross-sectional studies may be transformed to a cohort study by linkage to registries.
- We could ask about cancer in HUNT1 1984-1986, but then we would not know whether:
  - PA→cancer ?
  - Cancer→PA ?



Research Articles

Recreational Physical Activity and Cancer Risk in Subsites of the Colon (the Nord-Trøndelag Health Study)

Tom I.L. Nilsen, Pål R. Romundstad, Hermod Petersen, David Gunnell, and Lars J. Vatten

DOI: 10.1158/1055-9965.EPI-07-0746 Published January 2008



Det medisinske fakultet

#### Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

## **Cross-sectional studies cont.**

Disadvantages:

- Both exposures and outcomes are sampled at the same time. Dimension of time not taken into account, and no follow-up.
- Cannot address causation, since we do not know when exposure occurred relative to the outcome.

Advantages:

- Resource efficient (time and cost)
- Can study many variables (exposures and outcomes)

Det medisinske fakultet

#### Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

## **Cross-sectional studies cont.**

#### Methods used

- Regression analysis that do not rely on a temporal component:
  - Logistic regression
  - Linear regression
  - Poisson regression

Typical effect measure

- Regression coefficient (linear regression)
- Risk/probability ratio (Poisson regression without person time)
- Odds ratio (logistic regression)

Det medisinske fakultet

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

## **Observational designs**

- Ecological studies
- Cross-sectional studies
- Case-control studies
- Cohort studies

Det medisinske fakultet

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

# **Case-control studies**

- We start with the cases and collect information about exposures from the past
- Next, we contact controls who are disease-free and collect information about exposures from the past



Det medisinske fakultet

# Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions Case-control studies cont.

#### Example (Aydin et al.)

The CEFALO Study

- Identified childhood tumors in the Cancer Registry of Norway.
- Research groups travelled across Norway to inteview cases and controls about mobile phone use and potential confounding factors

DOI: 10.1093/jnci/djr244 Advance Access publication on July 27, 2011. © The Author 2011. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

#### ARTICLE

#### Mobile Phone Use and Brain Tumors in Children and Adolescents: A Multicenter Case–Control Study

Denis Aydin, Maria Feychting, Joachim Schüz, Tore Tynes, Tina Veje Andersen, Lisbeth Samsø Schmidt, Aslak Harbo Poulsen, Christoffer Johansen, Michaela Prochazka, Birgitta Lannering, Lars Klæboe, Tone Eggen, Daniela Jenni, Michael Grotzer, Nicolas Von der Weid, Claudia E. Kuehni, Martin Röösli

Manuscript received February 9, 2011; revised May 27, 2011; accepted June 7, 2011.

Correspondence to: Martin Röösli, PhD, Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Socinstrasse 57, PO Box, 4002 Basel, Switzerland (e-mail: martin.roosli@unibas.ch).

UiO **Institutt for medisinske basalfag** Det medisinske fakultet

# Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions Case-control studies cont.

#### Example (Østerlind et al.)

- All patients 20-79 yrs diagnosed with malignant melanoma 1/10-82 - 31/3-85 in a region of East-Denmark, identified by Danish Cancer Registry
- April 1984 controls randomly drawn from the national population registry, same age group and geographic region
- Cases and controls examined and interviewed



Article

# The Danish case-control study of cutaneous malignant melanoma. I. Importance of host factors

A. Østerlind, M. A. Tucker, K. Hou-Jensen, B. J. Stone, G. Engholm, O. M. Jensen

First published: 15 August 1988 | https://doi.org/10.1002/ijc.2910420210 | Citations: 120

# Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions Case-control studies cont.

#### Example (Østerlind et al.) cont.

	≥5 nevi	No nevi
Cases	76	231
Controls	39	635

$$OR = \frac{76 \cdot 635}{39 \cdot 231} = 5.4 \qquad 95\% \text{ Cl} (3.5, 8.1)$$

*Logistic regression* adjusted for age, freckles, hair color, skin color: *OR*=5.1 (95% CI (3.3, 7.9)).

For rare diseases like melanoma *OR*≈RR

#### Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

## **Case-control studies cont.**

- Controls must be drawn from the same source population as the cases.
- The statistical power can be increased by inclusion of more than one control per case (rare diseases or when case acquisition is expensive).
- Some studies are matched, e.g., by age and sex. Individual matching must be taken into account in the statistical analysis. Not possible to study the effect of a matching variable.

Det medisinske fakultet

#### Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

## **Case-control studies cont.**

Odds ratio in case-control studies:

- Important: Depends on the sampling of controls:
- Selected from person-time at risk (the study base available for matching <u>at each case's</u> <u>diagnosis</u>): odds ratio = rate ratio
- Selected from persons at risk (the basepopulation at risk at the <u>beginning</u> of followup): odds ratio = risk ratio
- Selected from survivors (the population at risk at the <u>end</u> of follow-up): odds ratio = odds ratio

International Journal of Epidemiology © International Epidemiological Association 1993 Vol. 22, No. 6 Printed in Great Britain

# What Does the Odds Ratio Estimate in a Case-Control Study?

NEIL PEARCE\*.\*

Pearce N (Department of Medicine, Wellington School of Medicine, PO Box 7343 Wellington, New Zealand). What does the odds ratio estimate in a case-control study? *International Journal of Epidemiology* 1993; 22: 1189-1192. The use of the term 'odds ratio' in reporting the findings of case-control studies is technically correct, but is often

Det medisinske fakultet

# Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

# **Case-control studies cont.**

Advantages:

- Generally relatively quick and inexpensive to implement
- Appropriate for rare diseases
- Wide range of exposures can be studied
- Well-suited when exposure assessment is demanding (e.g. biomarkers).

Disadvantages:

- Inappropriate for rare exposures
- Only possible to study one disease.
- Exposure is recorded after disease diagnosis. Recall bias may occur.
Det medisinske fakultet

## Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions Case-control studies cont.

Methods used

- Regression techniques
  - Logistic regression
  - Conditional logistic regression (matched studies)

- Odds ratio (logistic regression with control-sampling among survivors)
- Risk ratio (logistic regression with control-sampling among persons at risk)
- Rate ratio (logistic regression control-sampling among from person-time at risk incidence density sampling)

Det medisinske fakultet

## Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions Case-control studies cont.

Methods used

- Regression techniques
  - Logistic regression
  - Conditional logistic regression (matched studies)

- Odds ratio (logistic regression with control-sampling among survivors)
- Risk ratio (logistic regression with control-sampling among persons at risk)
- Rate ratio (logistic regression control-sampling among from person-time at risk incidence density sampling)

Det medisinske fakultet

## Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions Case-control studies cont.

Methods used

- Regression techniques
  - Logistic regression
  - Conditional logistic regression (matched studies)

- Odds ratio (logistic regression with control-sampling among survivors)
- Risk ratio (logistic regression with control-sampling among persons at risk)
- Rate ratio (logistic regression control-sampling among from person-time at risk / incidence density sampling)

Det medisinske fakultet

## Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions Case-control studies cont.

Methods used

- Regression techniques
  - Logistic regression
  - Conditional logistic regression (matched studies)

- Odds ratio (logistic regression with control-sampling among survivors)
- Risk ratio (logistic regression with control-sampling among persons at risk)
- Rate ratio (logistic regression control-sampling among from person-time at risk / incidence density sampling)

Det medisinske fakultet

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

### **Observational designs**

- Ecological studies
- Cross-sectional studies
- Case-control studies
- Cohort studies

Det medisinske fakultet

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

## **Cohort studies**

A group of subjects, a cohort, is followed forward in time. Exposure recorded at study start, before disease diagnosis. Disease incidence is recorded during follow-up.



Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

### **Cohort studies cont.**

Example of the Cancer Registry of Norway's Offshore Worker Cohort



Det medisinske fakultet

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

### **Cohort studies cont.**

Effect measure: Incidence rate ratio (IRR)

$$IRR = \frac{insidence \ rate \ among \ the \ exposed}{insidence \ rate \ among \ the \ non-exposed}$$

Det medisinske fakultet

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

### **Cohort studies cont.**

	Exposed	Non-exposed
No. with outcome	s <sub>e</sub>	s <sub>0</sub>
No. of person- years	t <sub>e</sub>	$t_0$
Incidence rate	IR <sub>e</sub>	$IR_0$

$$IRR = \frac{IR_e}{IR_0} = \frac{s_e/t_e}{s_0/t_0}$$

95% CI:

$$(IRR \cdot e^{-1.96\sqrt{1/s_e + 1/s_0}}, IRR \cdot e^{1.96\sqrt{1/s_e + 1/s_0}})$$

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

## **Cohort studies cont.**

#### Example (Veierød et al.) The Women's Lifestyle and Health Cohort Study

106 379 women aged 30-50 in 1991/92 repsonded to a questionnaire on sun tanning habits.

Followed up until 31-Dec-1999

Sunbrun at age 10-19 years and melanoma:

- Exposed:
  21 273 with sunburns ≥2 times/yr: 55 got melanoma
- Unexpoed

22 747 had never been sunburned: 22 got melanoma

Det medisinske fakultet

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

## **Cohort studies cont.**

Example (Veierød et al.) cont.: The Women's Lifestyle and Health Cohort Study

	Sunburn ≥2	Never
	times/yr	sunburned
	10-19 yrs	10-19 yrs
No. of melanoma cases	55	22
No. of person years	173 216	177 537
Insidence rate	0.000317	0.000124

$$IRR = \frac{55/173\ 216}{22/177\ 537} = 2.56$$
 95% KI (1.56, 4.20)

*Poisson regression* adjusted for age, region of residence, and hair color: *IRR*=2.42 (95% CI (1.46, 4.02)) Det medisinske fakultet

#### Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

## **Cohort studies cont.**

Advantages:

- Exposure is assessed before disease diagnosis (recall bias not an issue as in case-control studies).
- Several exposures and outcomes can be studied, exposure can be updated during follow-up, and incidence rate is easily estimated.

Disadvantages:

- Can be unsuitable for rare diseases which would require large cohorts. Long follow-up may be necessary, and thus the study may become expensive.
- Disease diagnosis may evolve over time, and loss to follow-up can also occur.

Det medisinske fakultet

## Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions Cohort studies cont.

Methods used

- Regression analysis (time-to-event)
  - Poisson regression
  - Cox regression

- Incidence rate ratios (Poisson regression)
- Hazard ratios (Cox regression)

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

## Summary methods for observational designs

Multivariable regression techniques play an essential role in the adjustment for confounding :

- Linear or logistic regression in ecological and cross-sectional studies
- Logistic regression in case-control studies (conditional logistic regression if the study is matched on an individual level)
- Cox or Poisson regression in cohort studies

Det medisinske fakultet

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

# *Overview: Observational designs*

- Ecological studies
- Cross-sectional studies
- Case-control studies
- Cohort studies



Table 1.2 in Veierød M.B., Lydersen S., Laake P. (eds.) *Medical statistics in clinical and epidemiological research*. Gyldendal Akademisk, 2012. <u>www.medicalstatistics.no</u>

Det medisinske fakultet

#### Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

## Many more....

- Retrospecitive cohort study
- Nested case-control study
- Case-cohort study
- Case-crossover study
- Matched cohort study

## 15 min break

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

## **Outline Part II. Clinical studies/summary:**

- Evidence and RCT
- Study planning
- RCT designs
- Randomization
- Blinding
- RCT analyses
- Summary and bias
- Case: Group discussion

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

## **Clinical research definition (National Institutes of Health, 2011):**

Medical research that involves people to test new treatments and therapies

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

## **Evidence and RCT - Randomized controlled trial**

- Gold standard for evaluating health care interventions in clinical and epidemiological research.
- $\geq$ 2 interventions are compared, one is control.
- Study participants allocated at random to eliminate bias
- Blinding of the group assignment to the clinicians/caregivers, and the assessors is recommended (if possible) to avoid bias.



Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

## **Evidence and RCT cont.**

#### Intervention

- Biomedical or behavioural
  - For example
  - Medication
  - Surgery
  - Diet
  - Physical activity
  - Physiotherapy
  - Acupuncture
  - Information

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

## **Study planning**

### Predefined and registered protocol must include

- 1. Aim
- 2. Hypotheses
- 3. Study sample (inclusion/exclusion criteria)
- 4. Study conduct
- 5. Randomization
- 6. Variables

- 7. Sample size
- 8. Procedures
- 9. Handling missing values
- 10. Statistical analysis

Det medisinske fakultet

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

## Aim

Example

• To investigate whether a new drug has a different effect than standard treatment on a specific disease

Purpose Hypothesis



Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

## Hypothesis: Specification of the null-hypothesis

- H<sub>0:</sub> A and B do not have different effect
- H<sub>A</sub>: A and B do have different effect (two-sided test)

A and B could be for example

- A=New treatment, B=Standard treatment
- A=New treatment, B=Placebo

## Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

## Inclusion/Exclusion criteria

• Factors that allow someone to participate in a clinical trial are *inclusion criteria*. Those that exclude or not allow participation are *exclusion criteria*.

Consider generalization

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

## Variables

Examples on different treatments/interventions and outcomes :

- Example 1:
  - Treatment: medication
  - Outcome: survival after cancer
- Example 2:
  - Treatment: Physical activity
  - Outcome: Quality of life after cancer
- Example 3:
  - Treatment: Vitamin D
  - Outcome: Lung function after COVID-19

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

## Sample size

• Another lecture

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

## **RCT designs**

#### Parallel group study



Intervention groups are independent and the analysis consists of *between subject* comparisons. Simplest and most commonly used RCT design is the individually randomized, two group, parallel study.

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

## **RCT designs cont.**

#### Parallel group study

#### Advantages:

- Behandlingsresultatene fra de forskjellige gruppene kan være uavhengige
- Ingen carry-over effekt som vi skal se at vi kan ha i kryss-over studier

#### Disadvantages:

- Gruppene kan initialt bli lite sammenlignbare, kan ofte løses ved blokkrandomisering (kommer snart)
- Antall pasienter kan bli stort spesielt hvis vi har mange grupper der hver gruppe bør ha en viss størrels

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

## RCT designs cont.

#### Parallel group study: example

The International Neonatal Immunotherapy Study (INIS) Collaborative Group (NEJM 2011)

- Parallel group RCT
- Immune globulin vs placebo in the treatment of neonatal sepsis, a major cause of death in newborn infants.
- *n*=3493 infants that were receiving antibiotics for the treatment of proven or suspected serious infection.
- *Double-blind* study: infants were randomly assigned to treatment in a blinded fashion and both treatments were given as identical injections (immune globulin, n = 1759; placebo, n = 1734).
- *Primary outcome* was death or disability when the child was two years old.

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

## **RCT designs cont.**

#### **Crossover study**

- Sometimes convenient to perform *within-subject* comparisons, e.g., to evaluate medications with a limited therapeutic window in cases of chronic disease.
- Each participant is randomly allocated to an intervention sequence and receives each intervention, one after the other.



Wash-out

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

## **RCT designs cont.**

Crossover study cont.

#### Advantages:

- Within-subject measurements usually have less variation than betweensubject variation, i.e., smaller study sample is required than in a parallel group study.
- The participant is its own control, can discover patient preferences, e.g., in a study comparing treatments for migraine.

**Disadvantages:** 

- Total study period is longer, all participants must complete all intervention periods to prevent loss of power.
- Not appropriate for curable short-term diseases.

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

## Randomization – why do it?

- Why? To remove investigator bias in the allocation of participants and tends to produce study groups comparable with respect to known as well as unknown risk factors.
- Why? To prevent that the estimated treatment effects are biased by confounding factors.

## Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions Randomization cont.

#### Simple randomization

Example

Two treatments A and B.

Randomization

Coin

 List of random digits (computer generated or from a table) Digits 0-4 gives A, 5-9 gives B: 0 5 2 7 8 4 3 gives A B A B B A A

Computer programs and websites for randomization

Easy to implement, and completely unpredictable. May result in a substantial imbalance in group size between the interventions.
Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

### Randomization cont.

#### **Block randomization**

Aim: balanced groups

#### Example

Two treatments A and B

- 4 patients per block.
- List of random numbers where
  1: AABB, 2: ABAB, 3: ABBA,
  4: BBAA, 5: BABA, 6: BAAB
  (0, 7-9 ignore).
- 0 5 2 7 8 4 3 ... gives - BABA ABAB - - BBAA ABBA..

Slightly predictable: allocation of the first three subjects is known, the investigator can then predict the allocation of the next subject. Can be avoided if the block sizes are varied at random, for example, between four, six, and eight.

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

## Randomization cont.

#### **Stratified randomization**

- Stratify with respect to known prognostic factors.
- The number of subjects within a stratum can be small, so blocked randomization is recommended within each stratum to ensure balanced allocation.

Table 5.5. An example of random permuted blocks within strata for a



- OBS: Block randomization and stratified randomization is not the same!
  - We block to secure equal N
- We stratified to get groups with equal values on important prognostic variables
- Blocking and stratification can be combined

UiO **Institutt for medisinske basalfag** Det medisinske frederigel:

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

### **Randomization cont.**

Example Rossebø et al.:

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

#### Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis

Anne B. Rossebø, M.D., Terje R. Pedersen, M.D., Ph.D., Kurt Boman, M.D., Ph.D., Philippe Brudi, M.D., John B. Chambers, M.D., Kenneth Egstrup, M.D., Ph.D., Eva Gerdts, M.D., Ph.D., Christa Gohlke-Bärwolf, M.D., Ingar Holme, Ph.D., Y. Antero Kesäniemi, M.D., Ph.D., William Malbecq, Ph.D., Christoph A. Nienaber, M.D., Ph.D., Simon Ray, M.D., Terje Skjærpe, M.D., Ph.D., Kristian Wachtell, M.D., Ph.D., and Ronnie Willenheimer, M.D., Ph.D., for the SEAS Investigators\*

# Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions Randomization cont.

Example Rossebø et al. cont.:

SEAS placebo group. During this process, neither the patients nor the investigators were aware of study-group assignments. After a 4-week run-in period in which all patients were given singleblind placebo tablets and were instructed to follow a lipid-lowering diet according to the recommendations of the National Cholesterol Education Program,<sup>36</sup> eligible patients underwent randomization in a 1:1 fashion in blocks of two to receive either simvastatin–ezetimibe or placebo (Fig. 1).

Gives a clear description of the method of randomization

# Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions Randomization cont.

#### Example Rossebø et al. cont.:

- 1:1, equal sample size in the two groups
- Two treatments, blocks of two patients. E.g. used list of random numbers and assigned:
  - AB for digits 0-4
  - BA for digits 5-9
- Randomization list:

0	5	2	7	8	Etc
AB	BA	AB	BA	BA	Etc

# Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions Blinding

Blinding of participants. Two purposes:

- Placebo effect
  - Knowledge of the treatment may affect the outcome
- Information bias
  - Knowledge of the treatment may affact the participants reporting of symptoms

Blinding of MD / researcher to avoid biased medical treatment/follow-up care

# Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions Blinding cont.

- Double blinded study: Neither the patient nor the investigator or the person who evaluate the response, know what treatment the patient gets
- The purpose of bliniding is to reduce both <u>known</u> and <u>unknown</u> errors. All patients have equal expectations to the treatment, get the same care and the same unbiased evaluation

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

## **Statistical analysis**

- Intervention effects in RCTs may often be analyzed by a *univariable method*, a method involving only one exposure and the outcome.
- Parallel group study:
  - Continuous outcome: a *t*-test can be used to study differences in the outcome between two intervention groups or a one-way analysis of variance if more than two groups are compared
  - Categorical outcome: Pearson's chi-squared test can be used to compare a dichotomous outcome in two or more groups in large samples
  - The outcome is an event, i.e., time to event data: Kaplan-Meier plots of estimated survival functions in the intervention groups and comparison of two survival curves by the logrank test

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

## Statistical analysis cont.

- Interventions are assigned by randomization to eliminate confounding bias, and adjustment by a *multivariable method* may be less necessary than in observational studies.
- Regression is often used to adjust for baseline measurements (Vickers and Altman, BMJ 2001)
- Confounding may still occur. For a variable to be a confounder in an RCT, it must differ between the comparison groups and predict the outcome of interest (CONSORT). A multivariable method is used when adjustment is sensible (Moher et al., BMJ 2010). See also review by Yu et al (Trials 2010)
- It is recommended to adjust for stratification variables

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

### Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis

Anne B. Rossebø, M.D., Terje R. Pedersen, M.D., Ph.D., Kurt Boman, M.D., Ph.D., Philippe Brudi, M.D., John B. Chambers, M.D., Kenneth Egstrup, M.D., Ph.D., Eva Gerdts, M.D., Ph.D., Christa Gohlke-Bärwolf, M.D., Ingar Holme, Ph.D., Y. Antero Kesäniemi, M.D., Ph.D., William Malbecq, Ph.D., Christoph A. Nienaber, M.D., Ph.D., Simon Ray, M.D., Terje Skjærpe, M.D., Ph.D., Kristian Wachtell, M.D., Ph.D., and Ronnie Willenheimer, M.D., Ph.D., for the SEAS Investigators\*

Det medisinske fakultet

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

#### STATISTICAL ANALYSIS

The study outcomes were analyzed according to the intention-to-treat principle. The study had a power of 90% to detect a reduction of 22% in the relative risk of the primary outcome. For all time-

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

### Statistical analysis cont.

Intention-to-treat analysis

 If some subjects do not follow the allocated intervention, an *intention-to-treat* analysis is recommended to avoid bias (Moher et al., BMJ 2010). Then all subjects are included in the analysis in the groups to which they were originally allocated.

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

## Statistical analysis cont.

#### Intention-to-treat:

biased against finding an effect (concervative)

(Some patients may receive the other group's treatment, the treatment difference may be smaller than it should be)

Analysing by treatment actually received (on treatment analysis/per protocol): biased in favour of showing a difference

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions



Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

## Summary

#### Grading the evidence in terms of causality of a supposed association

Study type	Reasoning
Ecological study	Descriptive; association on group level may be used for <b>development of broad hypotheses</b>
Cross-sectional study	Descriptive; individual association may be used for development and specification of hypotheses
Case-control study	Increased prevalence of risk factor among diseased may indicate a causal relationship
Cohort study	Increased risk of disease among exposed indicates a causal relation
Intervention study	Modification (reduction) of the incidence rate of the disease <b>confirms a causal relationship</b>

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

## Summary

#### **Random and systematic error**



Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

## Summary

#### Random and systematic error cont'd

- A: Low random and low systematic error = high precision and high validity
- **B:** Low random and high systematic error = high precision and low validity
- **C:** High random and low systematic error = low precision and high validity
- **D:** High random and High systematic error = low precision and low validity



Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

## Summary

#### Internal and external validity

- Inadequacies in the design, conduct, or analysis of a study will give <u>biased effect</u> <u>estimates</u>.
- Internal validity implies that there is no bias in the way the data is collected, analyzed, and interpreted.
- Internal validity is a prerequisite for *external validity*, i.e., <u>generalizability</u> of the study results to subjects outside the study sample.

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions



#### Confounder

A confounder is a variable that is

1) associated with the disease (either as a cause or a proxy for a cause but not as an effect of a disease),

- 2) associated with the exposure, and
- 3) not an effect of the exposure

Rothman KJ. Epidemiology. An Introduction. (2002)

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions Summary

#### Bias

- Selection bias: the study participants' representativeness in relation to the source population, can result from procedures used to select study participants.
- Information bias: occurs when exposure and/or disease are measured with measurement errors. The errors are typically due to instrument error and/or sampling error. Both systematic and random errors may cause biased effect estimates.
- **Confounding:** see previous slides

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

## Questions

• Epost: j.s.stenehjem@medisin.uio.no

Det medisinske fakultet

Part I. Epidemiological studies | Part II. Clinical studies/summary | Part III. Questions

## Summary methods for observational designs

#### Table 1.4Regression models.

Outcome	Regression model	Effect estimate	Chapter
Continuous data	Linear regression	Regression coefficient, $\hat{oldsymbol{eta}}$	4
Nominal data			
Two categories	Logistic regression	Odds ratio, $\widehat{OR} = e^{\hat{\beta}}$	3
>Two categories	Multinomial logistic regression	Odds ratio, $\widehat{OR} = e^{\hat{\beta}}$	3
Ordinal data	Ordinal logistic regression	Odds ratio, $\widehat{OR} = e^{\hat{\beta}}$	3
Count data	Poisson regression	Rate ratio, $\widehat{RR} = e^{\hat{\beta}}$	6
Time to event data	Cox regression	Hazard ratio, $\widehat{HR} = e^{\hat{\beta}}$	5
	Poisson regression	Incidence rate ratio, $\widehat{IRR} = e^{\hat{\beta}}$	6



Table 1.4 in Veierød M.B., Lydersen S., Laake P. (eds.) *Medical statistics in clinical and epidemiological research*. Gyldendal Akademisk, 2012. <u>www.medicalstatistics.no</u>